Nabriva: Publications

Safety, Tolerance and Pharmacokinetics of Single and Repeat Doses of
BC-3781, a Novel Antimicrobial

In Vivo Pharmacodynamic Activity of BC-3781

Pharmacokinetics, Mass Balance and Tissue Distribution of [14C]-BC-3205
in Non-pigmented Rats

Pharmacokinetics, Mass Balance and Tissue Distribution of [14C]-BC-3781
in Non-pigmented Rats

Antimicrobial Activity of the Investigational Pleuromutilin Compound
BC-3781 against Gram-positive Organisms Commonly Associated
with Cutaneous Infections

Activity of BC-3205 When Tested against a Collection of Gram-positive
Organism Responsible for Skin and Skin Structure Infections

Disk Diffusion and MIC Quality Control Ranges for BC-3205 and BC-3781,
Novel Pleuromutilin Class Antimicrobials

Correlation of In Vitro Susceptibility Testing Results for an
Investigational Pleuromutilin (BC-3781) Using MIC and Disk Diffusion
Methods Against Gram-Positive Pathogens

Correlations of Broth Microdilution MIC and Disk Diffusion Results for an
Investigational Agent, BC-3205 Among Potentially Indicated Species

In Vitro Antibacterial Spectrum of BC-7013, a Novel Peluromutilin
Derivative for Topical Use in Humans

In Vivo Pharmacodynamic Activity of BC-3205, a Novel Pleuromutilin
Derivative

In Vitro Antibacterial Spectrum of BC-3205, a Novel Pleuromutilin
Derivative for Oral Use in Humans

© Nabriva Therapeutics Forschungs GmbH